Literature DB >> 436915

Induction of tumor cell rejection in the low responsive YAC-lymphoma strain A host combination by immunization with somatic cell hybrids.

G Klein, E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 436915     DOI： 10.1016/0014-2964(79)90092-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  8 in total

1.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.

Authors:  H Sano; A Kosugi; S Sano; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 3.  Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants.

Authors:  L Larizza; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

4.  Isolated soluble fractions from the murine B16 melanoma induce primary in vitro syngeneic antitumor responses.

Authors:  B Y Klein; S Frenkel; D Naor
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Development of highly immunogenic variants of a rat fibrosarcoma line during in vitro cultivation.

Authors:  K Yamashina; T Oikawa; M Kasai; M Naiki; I Chiba; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 6.  Chemical xenogenization of experimental tumors.

Authors:  P Puccetti; L Romani; M C Fioretti
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.

Authors:  A Kosugi; J Shima; H Sano; M Ogata; T Kusama; H Fujiwara; T Hamaoka
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

Review 8.  Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.

Authors:  G Forni; H Fujiwara; F Martino; T Hamaoka; C Jemma; P Caretto; M Giovarelli
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.